-transparent.png){kind=logo}
When recombinant human interleukin 2 (r-IL-2) was given to mice by single subcutaneous (s.c.) injection it rapidly disappeared from the blood. However, administration of slowly released r-IL-2 using mini-osmotic pumps caused a significant prolongation of serum levels of IL-2. Using a method for assaying IL-2 in vivo, it was also demonstrated that both the viability and the cytotoxicity of lymphokine-activated killer (LAK) cells could be maintained at a high level in vivo by administration of slowly released r-IL-2 rather than by a single injection of r-IL-2. In addition, we successfully treated EL4-bearing mice by combination therapy consisting of LAK cells and slowly released r-IL-2.
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
January 1994,
European journal of cancer (Oxford, England : 1990),
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
January 1986,
Important advances in oncology,
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
January 1986,
Springer seminars in immunopathology,
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
August 1993,
Gan to kagaku ryoho. Cancer & chemotherapy,
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
February 1996,
Journal of neuro-oncology,
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
August 1988,
Cancer research,
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
January 1988,
Acta neurochirurgica,
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
August 1988,
Cancer,
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
January 1990,
Journal of neurosurgical sciences,
T Nishimura, and
Y Uchiyama, and
H Yagi, and
Y Hashimoto
September 1989,
Hepatology (Baltimore, Md.),
